Chronic disease will become commonplace ... for the international healthcare industry in addressing China’s looming Alzheimer’s challenge? Over the next 40 years in China, there is no ...

China approved Leqembi in January 2024 as a treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease, becoming the third country to do after the U.S. and Japan.

More convenient Alzheimer’s blood tests expected to be ready then could help Eisai reach a bigger share of China’s estimated 17 million people with early-stage disease, the spokesperson said.

Eisai and Biogen have a third regulatory approval for their amyloid-targeting Alzheimer’s disease therapy Leqembi, after it was greenlit by China’s National Medical Products Administration (NMPA).

Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau pathology in models of aging and dementia.

China - Robots, AI products widely applied to life, production scenarios in China (Voice_over) Highly developed products like ...

The neurodegenerative disorder affects millions of Americans, and its impact varies significantly across the country.

US pharmaceutical company Eli Lilly brings Memory Cafe to its booth at the ongoing 7th CIIE in collaboration with the ...

Longer-term, Eisai and Biogen are hoping for further evidence to support Leqembi from the phase 3 AHEAD 3-45 trial, which ...

due to Alzheimer’s disease (AD) and mild AD dementia. China is the third country to launch LEQEMBI following the United States and Japan. LEQEMBI selectively binds to soluble Aβ aggregates ...

According to a new study, Mahjong, a game that is popular in Asian countries, could slow cognitive deterioration and ...

On 23 October 2024, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Eli Lilly’s anti-amyloid beta (Aβ) monoclonal antibody (mAb) Kisunla for the treatment of patients with mild ...